1. Home
  2. VTYX vs PDCC Comparison

VTYX vs PDCC Comparison

Compare VTYX & PDCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTYX
  • PDCC
  • Stock Information
  • Founded
  • VTYX 2018
  • PDCC N/A
  • Country
  • VTYX United States
  • PDCC
  • Employees
  • VTYX N/A
  • PDCC N/A
  • Industry
  • VTYX Medicinal Chemicals and Botanical Products
  • PDCC
  • Sector
  • VTYX Health Care
  • PDCC
  • Exchange
  • VTYX Nasdaq
  • PDCC NYSE
  • Market Cap
  • VTYX 154.9M
  • PDCC 139.9M
  • IPO Year
  • VTYX 2021
  • PDCC N/A
  • Fundamental
  • Price
  • VTYX $2.08
  • PDCC $20.40
  • Analyst Decision
  • VTYX Buy
  • PDCC
  • Analyst Count
  • VTYX 4
  • PDCC 0
  • Target Price
  • VTYX $11.33
  • PDCC N/A
  • AVG Volume (30 Days)
  • VTYX 1.9M
  • PDCC N/A
  • Earning Date
  • VTYX 02-25-2025
  • PDCC N/A
  • Dividend Yield
  • VTYX N/A
  • PDCC N/A
  • EPS Growth
  • VTYX N/A
  • PDCC N/A
  • EPS
  • VTYX N/A
  • PDCC N/A
  • Revenue
  • VTYX N/A
  • PDCC N/A
  • Revenue This Year
  • VTYX N/A
  • PDCC N/A
  • Revenue Next Year
  • VTYX N/A
  • PDCC N/A
  • P/E Ratio
  • VTYX N/A
  • PDCC N/A
  • Revenue Growth
  • VTYX N/A
  • PDCC N/A
  • 52 Week Low
  • VTYX $1.67
  • PDCC N/A
  • 52 Week High
  • VTYX $11.48
  • PDCC N/A
  • Technical
  • Relative Strength Index (RSI)
  • VTYX 45.64
  • PDCC N/A
  • Support Level
  • VTYX $1.83
  • PDCC N/A
  • Resistance Level
  • VTYX $2.61
  • PDCC N/A
  • Average True Range (ATR)
  • VTYX 0.18
  • PDCC 0.00
  • MACD
  • VTYX -0.03
  • PDCC 0.00
  • Stochastic Oscillator
  • VTYX 32.26
  • PDCC 0.00

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About PDCC PEARL DIVER CREDIT COMPANY INC

PEARL DIVER CREDIT COMPANY INC is a non-diversified closed ended management investment company.

Share on Social Networks: